Bimatoprost is a prostaglandin analog indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. It is available as eye drops, implants and ophthalmic gel for intracameral use. MedsAcross supplies Bimatoprost for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. LATISSE ® is a prostaglandin analog, indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
Source: US FDA prescribing information
Bimatoprost is a structural prostaglandin analog. Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.
Source: US FDA prescribing information
Ensure the face is clean, makeup and contact lenses are removed. Once nightly, place one drop of LATISSE ® (bimatoprost ophthalmic solution) 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator. Do not reuse applicators and do not use any other brush/applicator to apply LATISSE ®. Do not apply to the lower eyelash line. Additional applications of LATISSE ® will not increase the growth of eyelashes.
Source: US FDA prescribing information
LATISSE ® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients. Hypersensitivity.
Source: US FDA prescribing information
Concurrent administration of LATISSE ® and intraocular pressure (IOP)-lowering prostaglandin analogs in ocular hypertensive patients may decrease the IOP-lowering effect. Patients using these products concomitantly should be closely monitored for changes to their IOP. Pigmentation of the eyelids and iris may occur. Iris pigmentation is likely to be permanent.
Source: US FDA prescribing information
The following adverse reactions are described elsewhere in the labeling: Effects on Intraocular Pressure Iris Pigmentation Lid Pigmentation Hair Growth Outside the Treatment Area Intraocular Inflammation Macular Edema Hypersensitivity Most common adverse reactions (incidence approximately 3% to 4%) are eye pruritus, conjunctival hyperemia, and skin hyperpigmentation.
Source: US FDA prescribing information
Store at 2º to 25ºC (36º to 77ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Bimatoprost, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Bimatoprost 0.3 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Bimatoprost 0.1 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Lumigan 0.1 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Latisse 0.3 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Durysta 10 mcg implantIntracameral Cold chain | Allergan | US FDA | Available on request |
| Zolymbus 0.01% ophthalmic gelOphthalmic | Thea Pharma | US FDA | Available on request |
4 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Bimatoprost in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 6 presentations of Bimatoprost and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 4 brand names for Bimatoprost, including Durysta, Latisse, Lumigan, Zolymbus.
Yes. The US FDA first approved Bimatoprost on 16 March 2001, according to Drugs@FDA.
Yes. Bimatoprost has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Bimatoprost must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Bimatoprost is classified under ATC code S01EE03 (Bimatoprost).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.